NCT06495892 PVP-Guided Decongestive Therapy in HF 2
| NCT ID | NCT06495892 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Başakşehir Çam & Sakura City Hospital |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 650 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 650 participants in total. It began in 2024-07-01 with a primary completion date of 2025-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.
Eligibility Criteria
Inclusion criteria * Hospitalization for heart failure (de novo or decompensated chronic heart failure) irrespective of left ventricular ejection fraction * Age 18-99 * Accept to participate Exclusion criteria * A prior history of upper extremity venous disease * Serum creatinine ≥ 3.5 mg/dL * Severe stenotic valvular disease * Hypertrophic obstructive cardiomyopathy * Withdrawal of consent * Indwelling central venous catheter, * Implanted left ventricular assist device * History of heart transplantation * Clinical diagnosis of cardiogenic shock * Any right-to-left shunt
Contact & Investigator
Emre K Aslanger, Prof
PRINCIPAL INVESTIGATOR
Basaksehir Pine and Sakura City Hospital
Frequently Asked Questions
Who can join the NCT06495892 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06495892 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06495892 currently recruiting?
Yes, NCT06495892 is actively recruiting participants. Contact the research team at mr_aslanger@hotmail.com for enrollment information.
Where is the NCT06495892 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye), Antalya, Turkey (Türkiye), Antalya, Turkey (Türkiye), Edirne, Turkey (Türkiye) and 11 additional locations.
Who is sponsoring the NCT06495892 clinical trial?
NCT06495892 is sponsored by Başakşehir Çam & Sakura City Hospital. The principal investigator is Emre K Aslanger, Prof at Basaksehir Pine and Sakura City Hospital. The trial plans to enroll 650 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.